A specialist from Oman, located at the crossroads of Africa and Asia, explains that his nation serves as a microcosm when it ...

Turkish immigrant Oguzhan Atay started the company in 2016 with a focus on prenatal testing. Now, he’s expanding to cancer ...

Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...

said Joanne Lager, MD, Chief Medical Officer. "The presentation highlights the growing demand for ZYNTEGLO, the first FDA-approved gene therapy for eligible patients with transfusion-dependent ...

Vertex Pharmaceuticals reported on Monday that it beat Wall Street estimates for third-quarter results, driven by strong demand for its cystic fibrosis treatments and early contributions from newer ...

Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin ...

Traditional medications are synthesized through chemical reactions, whereas biologics are derived from and reproduced, at ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

Thankfully, some companies can handle an inflationary environment and perform well throughout, while still registering the 12 ...

VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.

Analysts expect Vertex Pharmaceuticals to report an earnings per share (EPS) of $4.35. Investors in Vertex Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of ...

Vertex Pharmaceuticals Inc. reported third-quarter sales that beat analysts’ expectations as the biotech company’s mainstay ...